New omicron sublineages surge, but Pfizer-BioNTech bivalent booster retains effectiveness Post author: Post published: October 30, 2023 Post category:uncategorized The efficacy of the bivalent Pfizer-BioNTech COVID-19 messenger ribonucleic acid (mRNA) vaccine BNT162b2 BA.4/5. You Might Also Like Landmark discovery reshapes understanding of key cancer protein MCL-1 July 8, 2025 State-by-state snapshot: Long-COVID’s grip varies, with mental health in the crosshairs November 5, 2023 AIM Vaccine submits mRNA RSV vaccine for FDA clinical trials February 10, 2025
State-by-state snapshot: Long-COVID’s grip varies, with mental health in the crosshairs November 5, 2023